Stay updated on OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.

Latest updates to the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe update adds Revision: v3.4.2 and removes the prior government funding/operating status notices; overall study content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about government funding status and NIH operating status was added, and the page version was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedMinor UI and metadata updates only, no changes to core study content or functionality. The updates include adding a glossary toggle, capitalization tweaks to the update-status label, and a new revision/version indicator.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 in the page footer; no impact on study details, locations, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedLocations section was reorganized: explicit per-state locations (e.g., California, Colorado, Florida, etc.) were removed and replaced with a general 'Locations' heading listing regions, accompanied by a revision tag update from v3.3.2 to v3.3.3.SummaryDifference2%

- Check78 days agoChange DetectedRemoved the 'Certification/Extension First Posted' entry from the Study Record Dates. Other date entries, such as First Submitted and Last Update, remain shown.SummaryDifference0.1%

Stay in the know with updates to OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.